https://doi.org/10.55788/b3d258f0
Mucosal healing is an emerging treatment goal in the management of UC. One of the most widely used scores to evaluate this endpoint is the Nancy score, which allows the assessment of acute and chronic inflammatory disease activity in the mucosa. However, scoring histological images requires pathologistsâ training, which might not be available, especially in non-academic institutions or smaller hospitals. In addition, the subjectivity of the pathologist in the assessment may have been eliminated. To test this, Prof. Laurent Peyrin-Biroulet (Nancy University Hospital, France) and his team assessed whether an AI tool using image processing and machine learning algorithms, which assigns a Nancy index value to histopathology slides, could help assess histological disease activity [1].
Eight global sites submitted 600 UC histological images, which were added to the 200 images that were used in a preliminary smaller study. To train the algorithm, 90% of the probes were used and the other 10% were used for testing.
The cell and tissue regions of each training image were manually assessed by 3 histopathologists and assigned a Nancy index. These results were used to further train the AI, allowing the AI tool to fully characterise histological images, identify tissue types, cell types, cell numbers and locations, and measure the Nancy Index for each image.
The average intra-class correlation was 92.1% among the histopathologists and 91.1% between the histopathologists and the AI tool in all stages of disease progression. An even higher consensus was achieved at the extremes of the Nancy index.
This study shows that the robustness of the AI tool was substantially improved by the addition of a larger number of tissue samples while maintaining accuracy.
- Peyrin-Biroulet L, et al. Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites. P777, ECCO 2023, 01â04 March, Copenhagen, Denmark.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
Poor sleep in CD linked to low levels of vitamin D »
« Letter from the Editor Next Article
Poor sleep in CD linked to low levels of vitamin D »
Table of Contents: ECCO 2023
Featured articles
What Is New in Biologic Therapy?
Beneficial effect of early, post-operative vedolizumab on endoscopic recurrence in CD
Long-term data supports the established efficacy and safety of ustekinumab in UC
Anti-TNF withdrawal may be a safe option in stable IBD
Intensified drug therapy leads to better stricture morphology in CD
Small Molecules in IBD: State of the Art
Continued efficacy of long-term ozanimod as UC treatment
Upadacitinib successful in the management of both CD and UC
Solid results for long-term therapy of UC with filgotinib
Paediatric IBD: What You Need To Know
Perinatal period is crucial for the risk of developing CD
Early-life antibiotic exposure: a risk factor for paediatric-onset IBD
Paediatric patients with immune-mediated inflammatory disease harbour a heightened cancer risk
Risk Factors and Complications of IBD
Checking kidney function is important during the course of IBD
Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD
Surgical Approaches: New Developments
Long-term resection potentially better than anti-TNF treatment in CD
Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure
Pearls of the Posters
Drop in overall IBD procedures during the pandemic
Proton pump inhibitors associated with worse outcomes in CD
Poor sleep in CD linked to low levels of vitamin D
Novel AI tool assessing mucosal inflammation achieves high correlation with histopathologists
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com